R L Sutherland - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

R L Sutherland

Showing results (201-210 of 205) with videos related to

Pageof 21

Sort By:

You have reached the last page of results.This site can display upto 205 results.

Endocrine-Related Cancer|August 23, 2005

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatmentJ M W Gee, A Howell, W J Gullick, et al.

British Journal of Cancer|November 23, 2013

Adjuvant chemotherapy in elderly patients with pancreatic cancerA M Nagrial, D K Chang, N Q Nguyen, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2012

The prognostic and predictive value of serum CA19.9 in pancreatic cancerJ L Humphris, D K Chang, A L Johns, et al.

Oncogene|March 17, 2009

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcomeE K A Millar, J L Dean, C M McNeil, et al.

British Journal of Cancer|March 20, 2008

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitroP M O'Brien, M J Davies, J P Scurry, et al.

Pageof 21

Search research articles

Showing results (201-210 of 205) with videos related to

Sort By:

Pageof 21

You have reached the last page of results.This site can display upto 205 results.

Endocrine-Related Cancer|August 23, 2005

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatmentJ M W Gee, A Howell, W J Gullick, et al.

British Journal of Cancer|November 23, 2013

Adjuvant chemotherapy in elderly patients with pancreatic cancerA M Nagrial, D K Chang, N Q Nguyen, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2012

The prognostic and predictive value of serum CA19.9 in pancreatic cancerJ L Humphris, D K Chang, A L Johns, et al.

Oncogene|March 17, 2009

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcomeE K A Millar, J L Dean, C M McNeil, et al.

British Journal of Cancer|March 20, 2008

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitroP M O'Brien, M J Davies, J P Scurry, et al.

Pageof 21